Recurrent Respiratory Papillomatosis Medication
- Author: Eloise M Harman, MD; Chief Editor: Zab Mosenifar, MD, FACP, FCCP more...
No drug can cure RRP. Several drugs appear to slow the growth of papillomas and increase the interval between necessary surgical debulking procedures. Intralesional cidofovir is frequently effective; however, because optimal dosing and long-term effects are not known, it should probably be reserved for persons with moderate-to-severe disease. Dietary supplementation with oral indole-3-carbinol is often effective. Because of its adverse effects, treatment with interferon is now used infrequently as second-line therapy for patients with refractory severe disease. Control of gastroesophageal reflux is beneficial in children with RRP.
Certain types of vegetable extracts appear to improve symptoms.
Indole 3-carbinol (I3-C)
I3-C or its derivative, diindolylmethane (Indolplex), may be the active substance in cruciferous vegetables. I3-C changes the ratio of estradiol metabolites to the 2-hydroxyl derivative; this slows papilloma growth. Anecdotal experience demonstrates improvement in the disease with consumption of cabbage juice or a diet high in cruciferous vegetables (eg, cabbage, cauliflower, broccoli, Brussels sprouts). In clinical trials, one third of patients had a complete response and one third had a partial response to I3-C.
Nucleoside analogs are phosphorylated initially by viral thymidine kinase to eventually form a nucleoside triphosphate and inhibit viral replication.
Currently approved for treatment of CMV retinitis in AIDS. First member of a group of antivirals known as acyclic phosphonate nucleotide analogs. In infected cells, nucleotide analogs such as cidofovir inhibit viral DNA polymerase, which is responsible for replication of new viral RNA and DNA. Because HPV is the causal agent for RRP, eradication of the virus offers the potential for cure. Small trials have reported that intralesional use is beneficial. In a prospective trial of 16 RRP patients, 77% of the 13 patients available for follow-up experienced remission of disease after an average of 3.5 injections.
Inhibits viral DNA synthesis. A synthetic deoxyguanosine analog and the prototype antiviral agent that is activated by viral thymidine kinase. In small numbers of patients, acyclovir started on the day of surgical resection appeared to slow the rate of regrowth of papillomas. Combined treatment with interferon may decrease the rebound regrowth sometimes noted with interferon discontinuation.
Naturally produced proteins with antiviral, antitumor, and immunomodulatory actions. Alfa, beta, and gamma interferons may be administered topically, systemically, and intralesionally.
Interferon alfa-2a (Roferon A)
Exerts antiviral effects by inhibiting translation of viral proteins. In the absence of an effective antiviral agent, use of drugs that augment host defense is a reasonable approach. Seventy-five to 80% of patients respond to interferon, with a complete response in approximately 30%. Does not eradicate the virus, and relapse may occur after discontinuation of treatment. Usually is administered for at least 6 mo in patients who require more than 3-4 surgical procedures each year. Case reports suggest that combined treatment with acyclovir or retinoic acid may be beneficial in patients with recurrent disease during interferon treatment.
Verma H, Solanki P, James M. Acoustical and Perceptual Voice Profiling of Children With Recurrent Respiratory Papillomatosis. J Voice. 2015 Oct 13. [Medline].
Kosko JR, Derkay CS. Role of cesarean section in prevention of recurrent respiratory papillomatosis--is there one?. Int J Pediatr Otorhinolaryngol. 1996 Mar. 35(1):31-8. [Medline].
Shah KV, Stern WF, Shah FK, Bishai D, Kashima HK. Risk factors for juvenile onset recurrent respiratory papillomatosis. Pediatr Infect Dis J. 1998 May. 17(5):372-6. [Medline].
Karatayli-Ozgursoy S, Bishop JA, Hillel A, Akst L, Best SR. Risk Factors for Dysplasia in Recurrent Respiratory Papillomatosis in an Adult and Pediatric Population. Ann Otol Rhinol Laryngol. 2015 Oct 8. [Medline].
Kashima HK, Shah F, Lyles A, Glackin R, Muhammad N, Turner L. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope. 1992 Jan. 102(1):9-13. [Medline].
Armstrong LR, Preston EJ, Reichert M, Phillips DL, Nisenbaum R, Todd NW. Incidence and prevalence of recurrent respiratory papillomatosis among children in Atlanta and Seattle. Clin Infect Dis. 2000 Jul. 31(1):107-9. [Medline].
Armstrong LR, Derkay CS, Reeves WC. Initial results from the national registry for juvenile-onset recurrent respiratory papillomatosis. RRP Task Force. Arch Otolaryngol Head Neck Surg. 1999 Jul. 125(7):743-8. [Medline].
Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2000 Aug. 126(8):935-9. [Medline].
San Giorgi M, van den Heuvel ER, Tjon Pian Gi RE, Brunings JW, Chirila M, Friedrich G, et al. Age of onset of Recurrent Respiratory Papillomatosis: a distribution analysis. Clin Otolaryngol. 2015 Oct 13. [Medline].
Derkay CS, Malis DJ, Zalzal G, Wiatrak BJ, Kashima HK, Coltrera MD. A staging system for assessing severity of disease and response to therapy in recurrent respiratory papillomatosis. Laryngoscope. 1998 Jun. 108(6):935-7. [Medline].
Derkay CS, Hester RP, Burke B, Carron J, Lawson L. Analysis of a staging assessment system for prediction of surgical interval in recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2004 Dec. 68(12):1493-8. [Medline].
Chhetri DK, Shapiro NL. A scheduled protocol for the treatment of juvenile recurrent respiratory papillomatosis with intralesional cidofovir. Arch Otolaryngol Head Neck Surg. 2003 Oct. 129(10):1081-5. [Medline].
Derkay C; Multi-Disciplinary Task Force on Recurrent Respiratory Papillomas. Cidofovir for recurrent respiratory papillomatosis (RRP): a re-assessment of risks. Int J Pediatr Otorhinolaryngol. 2005 Nov. 69(11):1465-7. [Medline].
Lee AS, Rosen CA. Efficacy of cidofovir injection for the treatment of recurrent respiratory papillomatosis. J Voice. 2004 Dec. 18(4):551-6. [Medline].
Shehab N, Sweet BV, Hogikyan ND. Cidofovir for the treatment of recurrent respiratory papillomatosis: a review of the literature. Pharmacotherapy. 2005 Jul. 25(7):977-89. [Medline].
Higdon JV, Delage B, Williams DE, Dashwood RH. Cruciferous vegetables and human cancer risk: epidemiologic evidence and mechanistic basis. Pharmacol Res. 2007 Mar. 55(3):224-36. [Medline].
Rosen CA, Bryson PC. Indole-3-carbinol for recurrent respiratory papillomatosis: long term results. J of Voice. 2003. 18:248-53.
Healy GB, Gelber RD, Trowbridge AL, Grundfast KM, Ruben RJ, Price KN. Treatment of recurrent respiratory papillomatosis with human leukocyte interferon. Results of a multicenter randomized clinical trial. N Engl J Med. 1988 Aug 18. 319(7):401-7. [Medline].
Leventhal BG, Kashima HK, Mounts P, Thurmond L, Chapman S, Buckley S, et al. Long-term response of recurrent respiratory papillomatosis to treatment with lymphoblastoid interferon alfa-N1. Papilloma Study Group. N Engl J Med. 1991 Aug 29. 325(9):613-7. [Medline].
Gerein V, Rastorguev E, Gerein J, Jecker P, Pfister H. Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up. Ann Otol Rhinol Laryngol. 2005 Jun. 114(6):463-71. [Medline].
Shikowitz MJ, Abramson AL, Freeman K, Steinberg BM, Nouri M. Efficacy of DHE photodynamic therapy for respiratory papillomatosis: immediate and long-term results. Laryngoscope. 1998 Jul. 108(7):962-7. [Medline].
Endres DR, Bauman NM, Burke D, Smith RJ. Acyclovir in the treatment of recurrent respiratory papillomatosis. A pilot study. Ann Otol Rhinol Laryngol. 1994 Apr. 103(4 Pt 1):301-5. [Medline].
Lippman SM, Donovan DT, Frankenthaler RA, Weber RS, Earley CL, Hong WK, et al. 13-Cis-retinoic acid plus interferon-alpha 2a in recurrent respiratory papillomatosis. J Natl Cancer Inst. 1994 Jun 1. 86(11):859-61. [Medline].
Derkay CS, Volsky PG, Rosen CA, Pransky SM, McMurray JS, Chadha NK. Current use of intralesional cidofovir for recurrent respiratory papillomatosis. Laryngoscope. 2013 Mar. 123(3):705-12. [Medline].
Freed GL, Derkay CS. Prevention of recurrent respiratory papillomatosis: role of HPV vaccination. Int J Pediatr Otorhinolaryngol. 2006 Oct. 70(10):1799-803. [Medline].
Fusconi M, Grasso M, Greco A, Gallo A, Campo F, Remacle M, et al. Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol Ital. 2014 Dec. 34 (6):375-81. [Medline].
Shapiro AM, Rimell FL, Shoemaker D, Pou A, Stool SE. Tracheotomy in children with juvenile-onset recurrent respiratory papillomatosis: the Children's Hospital of Pittsburgh experience. Ann Otol Rhinol Laryngol. 1996 Jan. 105(1):1-5. [Medline].
Andrus JG, Shapshay SM. Contemporary management of laryngeal papilloma in adults and children. Otolaryngol Clin North Am. 2006 Feb. 39(1):135-58. [Medline].
Avidano MA, Singleton GT. Adjuvant drug strategies in the treatment of recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 1995 Feb. 112(2):197-202. [Medline].
Baker GE, Tyring SK. Therapeutic approaches to papillomavirus infections. Dermatol Clin. 1997 Apr. 15(2):331-40. [Medline].
Burns JA, Zeitels SM, Akst LM, Broadhurst MS, Hillman RE, Anderson R. 532 nm pulsed potassium-titanyl-phosphate laser treatment of laryngeal papillomatosis under general anesthesia. Laryngoscope. 2007 Aug. 117(8):1500-4. [Medline].
Chadha NK, James AL. Antiviral agents for the treatment of recurrent respiratory papillomatosis: a systematic review of the English-language literature. Otolaryngol Head Neck Surg. 2007 Jun. 136(6):863-9. [Medline].
Derkay CS, Smith RJ, McClay J, van Burik JA, Wiatrak BJ, Arnold J, et al. HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial. Ann Otol Rhinol Laryngol. 2005 Sep. 114(9):730-7. [Medline].
Green GE, Bauman NM, Smith RJ. Pathogenesis and treatment of juvenile onset recurrent respiratory papillomatosis. Otolaryngol Clin North Am. 2000 Feb. 33(1):187-207. [Medline].
Hawkes M, Campisi P, Zafar R, Punthakee X, Dupuis A, Forte V, et al. Time course of juvenile onset recurrent respiratory papillomatosis caused by human papillomavirus. Pediatr Infect Dis J. 2008 Feb. 27(2):149-54. [Medline].
Kimberlin DW. Current status of antiviral therapy for juvenile-onset recurrent respiratory papillomatosis. Antiviral Res. 2004 Sep. 63(3):141-51. [Medline].
Kimberlin DW, Malis DJ. Juvenile onset recurrent respiratory papillomatosis: possibilities for successful antiviral therapy. Antiviral Res. 2000 Feb. 45(2):83-93. [Medline].
Mouadeb DA, Belafsky PC. In-office laryngeal surgery with the 585nm pulsed dye laser (PDL). Otolaryngol Head Neck Surg. 2007 Sep. 137(3):477-81. [Medline].
Naiman AN, Ceruse P, Coulombeau B, Froehlich P. Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope. 2003 Dec. 113(12):2174-81. [Medline].
Pasquale K, Wiatrak B, Woolley A, Lewis L. Microdebrider versus CO2 laser removal of recurrent respiratory papillomas: a prospective analysis. Laryngoscope. 2003 Jan. 113(1):139-43. [Medline].
Pransky SM, Magit AE, Kearns DB, Kang DR, Duncan NO. Intralesional cidofovir for recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg. 1999 Oct. 125(10):1143-8. [Medline].
Preuss SF, Klussmann JP, Jungehulsing M, Eckel HE, Guntinas-Lichius O, Damm M. Long-term results of surgical treatment for recurrent respiratory papillomatosis. Acta Otolaryngol. 2007 Nov. 127(11):1196-201. [Medline].
Rady PL, Schnadig VJ, Weiss RL, Hughes TK, Tyring SK. Malignant transformation of recurrent respiratory papillomatosis associated with integrated human papillomavirus type 11 DNA and mutation of p53. Laryngoscope. 1998 May. 108(5):735-40. [Medline].
Rimell FL, Shoemaker DL, Pou AM, Jordan JA, Post JC, Ehrlich GD. Pediatric respiratory papillomatosis: prognostic role of viral typing and cofactors. Laryngoscope. 1997 Jul. 107(7):915-8. [Medline].
Schraff S, Derkay CS, Burke B, Lawson L. American Society of Pediatric Otolaryngology members' experience with recurrent respiratory papillomatosis and the use of adjuvant therapy. Arch Otolaryngol Head Neck Surg. 2004 Sep. 130(9):1039-42. [Medline].
Soma MA, Albert DM. Cidofovir: to use or not to use?. Curr Opin Otolaryngol Head Neck Surg. 2008 Feb. 16(1):86-90. [Medline].
Stamataki S, Nikolopoulos TP, Korres S, Felekis D, Tzangaroulakis A, Ferekidis E. Juvenile recurrent respiratory papillomatosis: still a mystery disease with difficult management. Head Neck. 2007 Feb. 29(2):155-62. [Medline].
Wiatrak BJ. Overview of recurrent respiratory papillomatosis. Curr Opin Otolaryngol Head Neck Surg. 2003 Dec. 11(6):433-41. [Medline].